Compound useful for the treatment of degenerative and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-9309244-B2
Application number	US-201514677058-A
Country	US
Kind code	B2
Filing date	Apr 2, 2015
Priority date	Jun 26, 2009
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I:

or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

First claim

What is claimed is:

1. A method for the treatment of psoriasis, comprising administering an amount of a compound according to Formula I:

or a pharmaceutically acceptable salt thereof sufficient to effect said treatment.

2. The method according to claim 1 , wherein the compound is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriasis.

3. The method according to claim 2 , wherein the compound is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriasis.

4. A method for the treatment of psoriasis, comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I:

or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment.

5. A method for the treatment of psoriasis, comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of a compound according to Formula I:

or a pharmaceutically acceptable salt thereof, and a further therapeutic agent, sufficient to effect said treatment.

6. The method according to claim 4 , wherein the pharmaceutical composition is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriasis.

7. The method according to claim 6 , wherein the pharmaceutical composition is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriasis.

8. The method according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of psoriasis.

9. The method according to claim 2 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

10. The method according to claim 3 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

11. The method according to claim 6 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

12. The method according to claim 7 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

13. The method according to claim 8 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

14. The method according to claim 9 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.

15. The method according to claim 10 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.

16. The method according to claim 11 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.

17. The method according to claim 12 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.

18. The method according to claim 13 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and Amevive ™, Enbrel ™, Humira ™, Remicade ™, Raptiva ™ and ustekinumab.

Assignees

• Galapagos Nv

Inventors

• Menet Christel Jeanne Marie
• Smits Koen Kurt

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/04

  specific for metastasis · CPC title